Admission hyperglycemia and outcomes in large vessel occlusion strokes treated with mechanical thrombectomy
Language English Country Great Britain, England Media print-electronic
Document type Journal Article
PubMed
28289148
DOI
10.1136/neurintsurg-2017-012993
PII: neurintsurg-2017-012993
Knihovny.cz E-resources
- Keywords
- Stroke, Thrombectomy,
- MeSH
- Stroke blood mortality surgery MeSH
- Hyperglycemia blood mortality surgery MeSH
- Brain Ischemia blood mortality surgery MeSH
- Blood Glucose metabolism MeSH
- Middle Aged MeSH
- Humans MeSH
- Patient Admission trends MeSH
- Prospective Studies MeSH
- Reperfusion adverse effects trends MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Thrombectomy adverse effects trends MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Blood Glucose MeSH
BACKGROUND AND PURPOSE: Higher admission serum glucose levels have been associated with poor outcomes in patients with acute ischemic stroke (AIS) treated with IV thrombolysis. We sought to evaluate the association of admission serum glucose with early outcomes of patients with emergent large vessel occlusion (ELVO) treated with mechanical thrombectomy (MT). METHODS: Consecutive AIS patients due to ELVO treated with MT in three tertiary stroke centers were evaluated. The following outcomes were documented using standard definitions: symptomatic intracranial hemorrhage (sICH), complete reperfusion, mortality, functional independence (modified Rankin Scale (mRS) score of 0-2), and functional improvement (shift in mRS score) at 3 months. The association of admission serum glucose and admission hyperglycemia (>140 mg/dL) with outcomes was evaluated using univariable and multivariable binary and ordinal logistic regression models. RESULTS: 231 AIS patients with ELVO (mean age 62±14 years, 51% men, median admission National Institute of Health Stroke Scale score 16 points (IQR 12-21), median admission serum glucose 125 mg/dL (IQR 104-162)) were treated with MT. Admission hyperglycemia was associated with a lower likelihood of functional improvement (common OR 0.53; 95% CI 0.31 to 0.97; p=0.027) and higher odds of 3 month mortality (OR 2.76; 95% CI 1.40 to 5.44; p=0.004) in multivariable analyses adjusting for potential confounders. A 10 mg/dL increase in admission blood glucose was associated with a higher likelihood of sICH (OR 1.07; 95% CI 1.01 to 1.13; p=0.033) and 3 month mortality (OR 1.07; 95% CI 1.02 to 1.12; p=0.004) in multivariable models. There was no association between admission serum glucose or hyperglycemia and complete reperfusion. CONCLUSIONS: Higher admission serum glucose and admission hyperglycemia are independent predictors of adverse outcomes in ELVO patients treated with MT.
Acute Stroke Unit Metropolitan Hospital Piraeus Greece
Australian Catholic University Sydney Australia
Department of Neurology University of Tennessee Health Science Center Memphis Tennessee USA
Department of Neurosurgery University of Tennessee Health Science Center Memphis Tennessee USA
Department of Radiology University of Tennessee Health Science Center Memphis Tennessee USA
International Clinical Research Center St Anne's Hospital Brno Czech Republic
References provided by Crossref.org